AlzeCure Pharma Stock Surges on Eli Lilly Collaboration

By EC Assets · Published 9 June 2026

AlzeCure Pharma shares increased significantly on Tuesday after the announcement of a new agreement. The company entered into a collaboration and out-licensing deal with Eli Lilly and Company. This development led to a substantial rise in AlzeCure Pharma's stock value. AlzeCure Pharma (ST:ALZCUR) shares rose by 301.4% on Tuesday. Investing.com reported this surge following the deal with Eli Lilly. The agreement is described as a collaboration and out-licensing arrangement. In related industry news, GSK announced an acquisition in the pharmaceutical sector. The company struck a $10.6 billion deal to purchase Nuvalent. This acquisition represents GSK's largest purchase in eight years. It aims to strengthen its cancer portfolio, which GSK had previously scaled back. UK pharmaceutical giant GSK acquired the U.S.-listed biotech company. This article is intended for informational purposes only. It does not constitute investment advice.